Theragnostics’ NephroScan Receives the US FDA’s Approval for the Treatment of Kidney Disease
Shots:
- The US FDA has approved NephroScan, a radiodiagnostic imaging drug that was used as an aid for the evaluation of renal parenchymal disorders in adult & pediatric patients including term neonates. The product was manufactured by ROTOP Pharmaka in Germany
- TC-99m DMSA imaging has been used to identify patients at risk for sequelae including hypertension, parenchymal scarring & chronic renal failure while radiologists also use Tc-99m DMSA imaging to split renal function, kidney shape, and position
- NephroScan is a sterile, single-dose kit used for the preparation of technetium Tc 99m succimer injection & marks the 1st US FDA therapy. GE Healthcare plans to distribute NephroScan in the US
Ref: PR Newswire | Image: Theragnostics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
